

Jessica A Hartmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1274891/publications.pdf>

Version: 2024-02-01

55
papers

2,085
citations

304743

22
h-index

254184

43
g-index

56
all docs

56
docs citations

56
times ranked

2736
citing authors

#	ARTICLE	IF	CITATIONS
1	Subjective and objective sleep in young people with borderline personality disorder features. <i>Journal of Sleep Research</i> , 2022, 31, e13463.	3.2	7
2	Baseline data of a sequential multiple assignment randomized trial (STEP study). <i>Microbial Biotechnology</i> , 2022, 16, 1130-1142.	1.7	0
3	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	2
4	Improving treatments for psychotic disorders: beyond cognitive behaviour therapy for psychosis. <i>Psychosis</i> , 2021, 13, 78-84.	0.8	14
5	Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population. <i>Microbial Biotechnology</i> , 2021, 15, 642-651.	1.7	11
6	Toward a Complex Network of Risks for Psychosis: Combining Trauma, Cognitive Biases, Depression, and Psychotic-like Experiences on a Large Sample of Young Adults. <i>Schizophrenia Bulletin</i> , 2021, 47, 395-404.	4.3	15
7	Distinguishing schizophrenia spectrum from non-spectrum disorders among young patients with first episode psychosis and at high clinical risk: The role of basic self-disturbance and neurocognition. <i>Schizophrenia Research</i> , 2021, 228, 19-28.	2.0	11
8	Intervention strategies for ultra-high risk for psychosis: Progress in delaying the onset and reducing the impact of first-episode psychosis. <i>Schizophrenia Research</i> , 2021, 228, 344-356.	2.0	19
9	Greater preference for eveningness is associated with negative symptoms in an ultra-high risk for psychosis sample. <i>Microbial Biotechnology</i> , 2021, 15, 1793-1798.	1.7	4
10	My child's future mental health: Carer's engagement with risk identification in an intervention study for youth with at-risk mental states. <i>Microbial Biotechnology</i> , 2021, , .	1.7	1
11	Patients'™, carers'™ and clinicians'™ attitudes towards alternative terms to describe the at-risk for psychosis state. <i>Schizophrenia Research</i> , 2021, 237, 69-75.	2.0	1
12	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 943-952.	3.1	5
13	The relation of basic self-disturbance to self-harm, eating disorder symptomatology and other clinical features: Exploration in an early psychosis sample. <i>Microbial Biotechnology</i> , 2020, 14, 275-282.	1.7	12
14	The neurophenomenology of early psychosis: An integrative empirical study. <i>Consciousness and Cognition</i> , 2020, 77, 102845.	1.5	51
15	Physical health assistance in early recovery of psychosis: Study protocol for a randomized controlled trial. <i>Microbial Biotechnology</i> , 2020, 14, 587-593.	1.7	6
16	Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes. <i>Schizophrenia Research</i> , 2020, 216, 255-261.	2.0	8
17	Transdiagnostic early intervention, prevention, and prediction in psychiatry. , 2020, , 27-37.		3
18	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. <i>Behaviour Research and Therapy</i> , 2020, 124, 103527.	3.1	16

#	ARTICLE	IF	CITATIONS
19	Clinical risk factors for psychosis. , 2020, , 249-268.		2
20	New paradigms to study psychosis risk. , 2020, , 399-416.		0
21	Pluripotential Risk and Clinical Staging: Theoretical Considerations and Preliminary Data From a Transdiagnostic Risk Identification Approach. <i>Frontiers in Psychiatry</i> , 2020, 11, 553578.	2.6	30
22	Does reason for referral to an ultra-high risk clinic predict transition to psychosis?. <i>Microbial Biotechnology</i> , 2019, 13, 318-321.	1.7	7
23	At-risk studies and clinical antecedents of psychosis, bipolar disorder and depression: a scoping review in the context of clinical staging. <i>Psychological Medicine</i> , 2019, 49, 177-189.	4.5	55
24	The construct validity of the Inventory of Psychotic-Like Anomalous Self-Experiences (IPASE) as a measure of minimal self-disturbance: Preliminary data. <i>Microbial Biotechnology</i> , 2019, 13, 686-691.	1.7	24
25	A Moving Target. , 2019, , 67-80.		0
26	The relationship between childhood trauma and clinical characteristics in ultra-high risk for psychosis youth. <i>Psychosis</i> , 2019, 11, 28-41.	0.8	6
27	Testing a neurophenomenological model of basic self disturbance in early psychosis. <i>World Psychiatry</i> , 2019, 18, 104-105.	10.4	23
28	Capturing the risk of persisting depressive symptoms: A dynamic network investigation of patients' daily symptom experiences. <i>Psychiatry Research</i> , 2019, 271, 640-648.	3.3	33
29	Effect of self-monitoring through experience sampling on emotion differentiation in depression. <i>Journal of Affective Disorders</i> , 2019, 244, 71-77.	4.1	35
30	Broad clinical high-risk mental state (CHARMS): Methodology of a cohort study validating criteria for pluripotent risk. <i>Microbial Biotechnology</i> , 2019, 13, 379-386.	1.7	76
31	Clinical trajectories in the ultra-high risk for psychosis population. <i>Schizophrenia Research</i> , 2018, 197, 550-556.	2.0	54
32	Prediction in mental health research and its limits (or why life can only be understood backwards but) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.7	5
33	Detail, dynamics and depth: useful correctives for some current research trends. <i>British Journal of Psychiatry</i> , 2018, 212, 262-264.	2.8	19
34	The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo. <i>Schizophrenia Research</i> , 2018, 195, 543-548.	2.0	28
35	Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry. <i>World Psychiatry</i> , 2018, 17, 133-142.	10.4	311
36	NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disordersâ€”medium-term follow-up and clinical course. <i>NPJ Schizophrenia</i> , 2018, 4, 11.	3.6	41

#	ARTICLE	IF	CITATIONS
37	Dynamic prediction of transition to psychosis using joint modelling. <i>Schizophrenia Research</i> , 2018, 202, 333-340.	2.0	18
38	Can We Jump from Cross-Sectional to Dynamic Interpretations of Networks Implications for the Network Perspective in Psychiatry. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 175-177.	8.8	96
39	Moving From Static to Dynamic Models of the Onset of Mental Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 528.	11.0	218
40	Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis. <i>Psychological Medicine</i> , 2017, 47, 616-626.	4.5	41
41	Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 292-299.	8.8	20
42	Economic evaluation of an experience sampling method intervention in depression compared with treatment as usual using data from a randomized controlled trial. <i>BMC Psychiatry</i> , 2017, 17, 415.	2.6	14
43	Further examination of the reducing transition rate in ultra high risk for psychosis samples: The possible role of earlier intervention. <i>Schizophrenia Research</i> , 2016, 174, 43-49.	2.0	47
44	The 5-HTTLPR genotype moderates the association between sleep quality and positive affect: A replication study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1350-1351.	0.7	3
45	Change in daily life behaviors and depression: Within-person and between-person associations.. <i>Health Psychology</i> , 2016, 35, 433-441.	1.6	47
46	Declining transition rates to psychotic disorder in "ultra-high risk" clients: Investigation of a dilution effect. <i>Schizophrenia Research</i> , 2016, 170, 130-136.	2.0	87
47	Experience Sampling-Based Personalized Feedback and Positive Affect: A Randomized Controlled Trial in Depressed Patients. <i>PLoS ONE</i> , 2015, 10, e0128095.	2.5	43
48	Effects of momentary self-monitoring on empowerment in a randomized controlled trial in patients with depression. <i>European Psychiatry</i> , 2015, 30, 900-906.	0.2	38
49	Exploring the Construct of Subjective Sleep Quality in Patients With Insomnia. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e768-e773.	2.2	34
50	A therapeutic application of the experience sampling method in the treatment of depression: a randomized controlled trial. <i>World Psychiatry</i> , 2014, 13, 68-77.	10.4	194
51	The serotonin transporter 5-HTTLPR polymorphism in the association between sleep quality and affect. <i>European Neuropsychopharmacology</i> , 2014, 24, 1086-1090.	0.7	15
52	Day-to-day associations between subjective sleep and affect in regard to future depression in a female population-based sample. <i>British Journal of Psychiatry</i> , 2013, 202, 407-412.	2.8	84
53	P.2.a.012 Evidence that self-reported sleep impacts on momentary affect in daily life and predicts follow-up depressive symptomatology. <i>European Neuropsychopharmacology</i> , 2012, 22, S230-S231.	0.7	0
54	Translating assessments of the film of daily life into person-tailored feedback interventions in depression. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 402-403.	4.5	43

#	ARTICLE	IF	CITATIONS
55	Momentary assessment technology as a tool to help patients with depression help themselves. <i>Acta Psychiatrica Scandinavica</i> , 2011, 124, 262-272.	4.5	108